REYON Pharmaceutical Co., Ltd.

KSE 102460.KS

REYON Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2023: 2.67%

REYON Pharmaceutical Co., Ltd. Operating Income Margin is 2.67% for the year ending December 31, 2023, a -44.48% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

REYON Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2022 was 4.81%, a 19.76% change year over year.
REYON Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2021 was 4.02%, a 25.82% change year over year.
REYON Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2020 was 3.19%, a -46.84% change year over year.
REYON Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2019 was 6.00%, a 200.18% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

KSE: 102460.KS

REYON Pharmaceutical Co., Ltd.

CEO	Ms. Soon-Ock Jung
IPO Date	June 10, 2010
Location	South Korea
Headquarters	416 Yeongdong-daero
Employees	466
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food Soft Drinks & Sodas

Description

REYON Pharmaceutical Co., Ltd. manufactures and sells finished medicines and APIs in South Korea and internationally. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years